POLY 412 |
| Liposome-based delivery technology has been established and used in clinic for the treatment of breast cancer. To address formulation and stability challenges of liposomes, many other types of delivery vehicles have been developed and are under preclinical or clinical evaluations. There is growing interest in using polymeric nanoparticles for the delivery of chemotherapeutics, especially after Abraxane, a polymer-paclitaxel nanoencapsulate, was approved by the FDA for breast cancer therapy. However, since doxorubicin is hydrophilic with an aqueous solubility of 10 mg/mL in its hydrochloride salt, encapsulation of doxorubicin into hydrophobic polymeric nanoparticles is very difficult. Only limited success was achieved with drawbacks including low encapsulate efficiency, large particle size and multimodal particle distribution. Addressing these difficulties, we report the formation of polylactide-doxorubicin nanoparticles with 27% drug loading, quantitative loading efficiency and unimodal size distribution. |
|
Synthetic and Biological Macromolecules for Emerging Nanotechnologies
6:00 PM-8:00 PM, Tuesday, August 21, 2007 BCEC -- Exhibit Hall - B2, Poster
Division of Polymer Chemistry |